Category Archives: TB

Findings indicate two newest TB drugs, bedaquiline and delamanid in combination safe, promising for patients with few options

By on .

A study following outcomes of 28 patients with drug-resistant tuberculosis in three countries with high burdens of the disease found what the researchers cite as strong evidence that a combination of the two newest TB drugs could be part of a safe and effective treatment regimen. The  drugs, bedaquiline — which was approved by the […]

TB Elimination: India can Lead the Way

By on .

As the United Nations High Level Meeting on HIV/AIDS gets underway today in New York, Indian Prime Minister Narendra Modi is meeting with Congress this week. Tuberculosis advocates are hoping to see Prime Minister Modi and members of Congress renew their commitment to eliminating TB in India, which has one of the highest TB burdens […]

WHO guidance on first new TB treatment in five decades offers hope, emphasizes monitoring

By on .

WHO cites need to prevent new drug resistance, protect first treatment advance in more than 40 years The World Health Organization’s release this week of  interim policy guidelines on the use of bedaquiline  for treatment of multidrug-resistant tuberculosis  offers hope to patients and their physicians running out of options to treat the disease, but the […]

TB Week: Survivors and allies recount illness, treatment, and loss

By on .

In the week leading up to International Tuberculosis Day, which commemorates the discovery by Robert Koch of the cause of the disease in 1882, Science Speaks will look at issues, events and efforts to confront this lasting and global health threat. When South African nurse Pat Bond got sick in 2010, doctors treated her for […]

US TB drug shortages highlight global gaps

By on .

This is how small the world of infectious diseases can be, and how recent the distant past. The patient who ended up at Baltimore’s Health Department in April 2011 had been treated with apparent success for tuberculosis before, in Kenya, where he was from. But now, he had a strain of the disease that was […]

FDA TB drug approval a milestone, with caveats

By on .

The U.S. Food and Drug Administration’s approval of the first new drug to treat tuberculosis in nearly half a century and the agency’s first use of its accelerated approval process to speed availability of TB medicine comes with cautions, and with a direction of work yet to be done, agency officials and treatment advocates agree. […]

FDA panel finds new type of TB drug effective, raising hopes for treatment of drug-resistant strains

By on .

Dr. Dalene von Delft had a choice between dying  or going deaf, and that was a choice only if the arduous treatment she was undergoing for drug-resistant tuberculosis worked. The South African pediatrician had contracted a resistant strain of the disease caring for patients, and the only potentially effective treatment was showing one of its […]

WHO 2012 Global Tuberculosis Report shows uneven progress

By on .

New cases of TB have been falling for several years, while access to care has expanded,  and deaths from tuberculosis have dropped by forty percent since the mid-1990s.  That’s some of the progress highlighted in the World Health Organization’s Global Tuberculosis Report released last week, and it means the target of halving the death rate […]

TB drug trial yields gains in drug-resistant disease treatment

By on .

A study following patients who had  participated in a trial of a potential new treatment for drug-resistant tuberculosis has shown heartening results, with nearly three-quarters of patients who took the medicine for six months or longer showing “favorable outcomes”  — cured  or completed treatment —  according to a study published in the European Respiratory Journal. […]

Study reveals effective preventive dose, pain drug for tuberculosis treatment, bad news and new steps in Uganda . . . and more

By on .

New approaches to disease treatment and prevention, as well as failures in old approaches are part of what we’re reading this week . . .   NIH-Funded analysis estimates effective PrEP dosing for men who have sex with men: An analysis of data from the iPrEx study looked at the amount of the antiretroviral medicine […]